ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist
(group practice)

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,527Medicare Part D Prescriptions Filled, Including Refills

Rank: 79 out of 1290

$973K Total Retail Price of All Prescriptions

Rank: 53 out of 1290

908 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 908 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

3% of this provider’s 8,186 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$102 was the average price of a prescription from this provider, compared to $94 among peers.

Prescriptions per Patient

10 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
LEVOTHYROXINE SODIUM 546 472 1 4
SIMVASTATIN 478 441 2 1
OMEPRAZOLE 280 243 3 2
LISINOPRIL 234 187 4 5
AMLODIPINE BESYLATE 231 226 5 3
METFORMIN HCL 209 172 6 10
METOPROLOL TARTRATE 204 176 7 7
FUROSEMIDE 199 172 8 9
HYDROCHLOROTHIAZIDE 147 137 9 20
GLIMEPIRIDE 147 143 9 57
CRESTOR 143 131 11 17
ATENOLOL 135 115 12 18
PRAVASTATIN SODIUM 131 119 13 42
CITALOPRAM HBR 124 103 14 29
METOPROLOL SUCCINATE 122 117 15 14
LOSARTAN POTASSIUM 111 107 16 19
TRAMADOL HCL 110 89 17 25
ZETIA 105 99 18 165
NEXIUM 103 53 19 34
SYNTHROID 103 79 19 28
ATORVASTATIN CALCIUM 97 93 21 23
LANTUS 91 78 22 67
ZOLPIDEM TARTRATE 88 77 23 15
INSULIN SYRINGE 84 70 24 76
PEN NEEDLE 82 69 25 72
HYDROCODONE-ACETAMINOPHEN 82 70 S3 25 6
AZITHROMYCIN 82 69 25 61
CLOPIDOGREL 82 72 25 24
LANTUS SOLOSTAR 79 71 29 88
GLYBURIDE 75 68 R 30 87
METFORMIN HCL ER 73 66 31 135
LISINOPRIL-HYDROCHLOROTHIAZIDE 73 70 31 92
DIOVAN 71 64 33 53
LOSARTAN-HYDROCHLOROTHIAZIDE 71 59 33 106
GABAPENTIN 69 63 35 8
AMITRIPTYLINE HCL 69 65 R 35 97
PLAVIX 66 61 37 32
CARVEDILOL 64 64 38 12
TRICOR 62 57 39 194
ALLOPURINOL 61 54 40 60
SERTRALINE HCL 59 53 41 36
JANUVIA 58 47 42 82
MELOXICAM 58 53 42 31
TRIAMTERENE-HCTZ 57 53 44 130
PANTOPRAZOLE SODIUM 56 51 45 48
GLYBURIDE-METFORMIN HCL 56 56 R 45 147
POTASSIUM CHLORIDE 53 46 47 35
CIPROFLOXACIN HCL 52 41 48 46
GEMFIBROZIL 52 39 48 210
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 18, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.